Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia

Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia

Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgic...

Full description

Bibliographic Details
Main Authors:	Murtuza Nuruddin, Soma Rani Roy, Fahmida Hoque
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Oman Journal of Ophthalmology
Subjects:	interferon-alpha-2a interferon-alpha-2b ocular surface neoplasm
Online Access:	http://www.ojoonline.org/article.asp?issn=0974-620X;year=2022;volume=15;issue=1;spage=81;epage=84;aulast=Nuruddin

Similar Items

Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists
by: Rachna Meel, et al.
Published: (2021-01-01)

Topical interferon alpha-2b for treatment of noninvasive ocular surface squamous neoplasia with 360° limbal involvement
by: Siamak Zarei-Ghanavati, et al.
Published: (2014-01-01)

“Interferon magic” in ocular surface squamous neoplasia
by: Sinumol Sukumaran Thulaseedharan, et al.
Published: (2018-01-01)

Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
by: Sonal S Chaugule, et al.
Published: (2018-01-01)

Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: Comparative analysis of outcomes based on original tumor configuration
by: Carol L Shields, et al.
Published: (2021-01-01)

Management of Ocular Surface Squamous Neoplasia in Association with Fungal Keratitis in a HIV Positive Individual
by: Prabhakar Singh, et al.
Published: (2021-02-01)

Update on pharmacotherapy for ocular surface squamous neoplasia
by: Ghada Al Bayyat, et al.
Published: (2019-08-01)

Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar
by: Mohammad Abu-Tineh, et al.
Published: (2020-03-01)

Cryotherapy after Topical Interferon Alpha 2b to Treat Conjunctival Primary Acquired Melanosis
by: Valentín Huerva, et al.
Published: (2023-03-01)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
by: Megen C. Wittling, et al.
Published: (2021-01-01)

Pathways of IFN-alpha Activation in Patients with Cervical Intraepithelial Neoplasia (CIN)
by: Nelson Ranieri Tirone, et al.
Published: (2021-11-01)

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy
by: Beatriz Alvarado-Castillo, et al.
Published: (2023-07-01)

Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients
by: Swathi Kaliki, et al.
Published: (2016-01-01)

Interferon alpha and non-specific markers of inflammation in patients with systemic lupus erythematosus
by: Lamija Zečević, et al.
Published: (2022-08-01)

Interferon alpha (IFN-α) in systemic lupus erythematosus (SLE)
by: Sara Moqbil, et al.
Published: (2022-11-01)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
by: Elson Vidal Martins Jr., et al.
Published: (2009-11-01)

Regression of nevi in a melanoma patient treated with interferon
by: Ayelet Rishpon, et al.
Published: (2012-04-01)

Descriptive study of incidence of side effects of Pegylated interferon alpha therapy and their relation to age, gender, duration of treatment and type of hepatitis in 50 Iraqi patients.
by: Khalid A. AL-Khazraji
Published: (2012-01-01)

Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients
by: Stanojević Ivan, et al.
Published: (2015-01-01)

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial
by: Chuan Li, et al.
Published: (2021-01-01)

Interferon alpha-2b in giant ocular surface squamous neoplasia
by: Erick Hernandez-Bogantes, et al.
Published: (2016-01-01)

Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients
by: Corina-Daniela Ene, et al.
Published: (2015-12-01)

The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis
by: Mehrdad Afarid, et al.
Published: (2016-01-01)

Epidermodisplasia verruciforme: tratamento combinado com acitretina e interferon alfa-2a Epidermodysplasia verruciformis: combined treatment with acitretin and interferon alpha-2a
by: Cristiana Silveira Silva, et al.
Published: (2006-12-01)

Amniotic membrane transplantation with topical interferon alfa-2b after excision of ocular surface squamous neoplasia
by: Hua-Tao Xie, et al.
Published: (2018-01-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients
by: Ji Hwan Lee, et al.
Published: (2018-02-01)

Interleukin‐2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: A retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College
by: Wencai Qi, et al.
Published: (2022-11-01)

Flaxseed Prevents Interferon-alpha Induced Depressive Behavior in Mice: the α-Linolenic Acid is Essential
by: Azadeh Mesripour*, et al.
Published: (2021-01-01)

Corneal melt in conjunctival intraepithelial neoplasia
by: Nichelle Warren, et al.
Published: (2020-09-01)

Insights Into Type I and III Interferons in Asthma and Exacerbations
by: Helen E. Rich, et al.
Published: (2020-09-01)

Effect of interferon-alpha on experimental septal fibrosis of the liver - study with a new model
by: Marcia Maria de Souza, et al.
Published: (2001-04-01)

An open, non-controlled clinical study to assess the efficacy and safety of the recombinant human alpha 2b pegylated interferon PEG-Heberon® plus ribavirin for the treatment of chronic hepatitis C virus infection in Cuban patients
by: Marlen I Castellanos-Fernández, et al.

Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects
by: Jana D. Albrecht, et al.
Published: (2022-05-01)

Extraction and fractionation of the seaweed Sargassum plagyophylum and evaluation of fractions on depression induced by interferon alpha in mice
by: Azadeh Mesripour, et al.
Published: (2022-01-01)

Significance of the interferon (IFN) in the therapy
by: Sabina Mahmutović, et al.
Published: (2004-11-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil
by: Maria Cassia Jacintho Mendes-Corrêa, et al.

Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha
by: Yisi Liu, et al.
Published: (2023-05-01)

Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha
by: Lan-Juan Zhao, et al.
Published: (2016-11-01)